Brodalumab for the treatment of plaque psoriasis: up-to-date

References

• Kivelevitch DN, Menter A. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis. Immunotherapy. 2015;7(4):323–333.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018 Sep 15;201(6):1605–1613.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015 Oct;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019 Jan;80(1):43–53.
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019 Jan;80(1):27–40.
   PubMed Web of Science ®Google Scholar
• Roman M, Chiu MW. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy. Drug Des Devel Ther. 2017;11:2065–2075.
   PubMed Web of Science ®Google Scholar
• Malakouti M, Brown GE, Wang E, et al. The role of IL-17 in psoriasis. J Dermatological Treat. 2015;26(1):41–44.
   PubMed Web of Science ®Google Scholar
• Senra L, Stalder R, Alvarez Martinez D, et al. Keratinocyte-derived IL-17E contributes to inflammation in psoriasis. J Invest Dermatol. 2016 Oct;136(10):1970–1980.
   PubMed Web of Science ®Google Scholar
• Rickel EA, Siegel LA, Yoon BR, et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol. 2008 Sep 15;181(6):4299–4310.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.
   PubMed Web of Science ®Google Scholar
• Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009 Feb;160(2):319–324.
   PubMed Web of Science ®Google Scholar
• Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013 Mar 1;190(5):2252–2262.
   PubMed Web of Science ®Google Scholar
• Russell C, Kerkof K, Bigler J, et al. Blockade of the IL-17R with AMG 827 leads to rapid reversal of gene expression and histopathologic abnormalities in human psoriatic skin. J Invest Dermatol. 2010;130:S46–S. NATURE PUBLISHING GROUP 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA; 2010.
   PubMed Web of Science ®Google Scholar
• Russell C, Kerkof K, Bigler J, et al. Blockade of the IL-17R with AMG 827 leads to rapid reversal of gene expression and histopathologic abnormalities in psoriatic skin, including substantial pathway-specific effects within one week. J Invest Dermatol. 2011;131:S11–S. NATURE PUBLISHING GROUP 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA; 2011.
   PubMed Web of Science ®Google Scholar
• Russell CB, Rand H, Bigler J, et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol. 2014 Apr 15;192(8):3828–3836.
   PubMed Web of Science ®Google Scholar
• Siliq (brodalumab) Label - FDA. 2018 [cited 2018]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf
   Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016 Aug;175(2):273–286.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012 Mar 29;366(13):1181–1189.
   PubMed Web of Science ®Google Scholar
• Menter A, Sobell J, Silverberg JI, et al. Long-term efficacy of brodalumab for the treatment of moderate-to-severe psoriasis: data from a pivotal phase 3 clinical trial. SKIN J Cutaneous Med. 2018;2(S1).
   Google Scholar
• Lebwohl M, Papp K, Tyring S, et al. Long-term efficacy of brodalumab for the treatment of moderate-to-severe psoriasis in two pivotal phase 3 clinical trials. J Am Acad Dermatol. 2018;79(3):AB180.
   Google Scholar
• Papp KA, Lebwohl MG. Onset of action of biologics in patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2017 Mar 1;17(3):247–250.
   PubMed Web of Science ®Google Scholar
• Sawyer LM, Cornic L, Levin LA, et al. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol JEADV. 2013;24(5):356–360.
   Google Scholar
• McMichael A, Desai SR, Qureshi A, et al. Efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis and skin of color: results from the pooled amagine-2/-3 randomized trials. Am J Clin Dermatol. 2018 Nov 23.
   PubMed Web of Science ®Google Scholar
• Bushnell DM, Martin ML, McCarrier K, et al. Validation of the psoriasis symptom inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013 Oct;24(5):356–360.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Zigmond A, Snaith R. The hospital anxiety and depression scale. ActaPsychiatrScand. 1983;67:361–370.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018 Jan;78(1):81–9.e5.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018 Aug;18(8):897–903.
   PubMed Web of Science ®Google Scholar
• Koo J, Marangell LB, Nakamura M, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol JEADV. 2017 Dec;31(12):1999–2009.
   PubMed Web of Science ®Google Scholar
• Cohen BE, Martires KJ, Ho RS. Psoriasis and the risk of depression in the US population: national health and nutrition examination survey 2009–2012. JAMA Dermatol. 2016 Jan;152(1):73–79.
   PubMed Web of Science ®Google Scholar
• Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016 Jan;74(1):190–192.
   PubMed Web of Science ®Google Scholar